Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Neuro-Oncology
Published in: Journal of Neuro-Oncology 3/2015

01-07-2015 | Editors' Invited Manuscript

Nanotechnology to augment immunotherapy for the treatment of glioblastoma multiforme

Authors: Nolan Ung, Isaac Yang

Published in: Journal of Neuro-Oncology | Issue 3/2015

Login to get access

Abstract

Glioblastoma multiforme (GBM) is characterized as one of the most common and most deadly malignant primary brain tumors. Current treatment modalities include the use of surgical resection and adjuvant chemotherapy and radiation therapy, though survival is still limited. Because of this, new treatment strategies are needed to improve overall survival. Immunotherapy has emerged as a potential treatment, but still possesses certain limitations to have a substantial clinical effect. In addition, nanotechnology has emerged as potent treatment effectors that have been shown to augment the effects of therapies including chemotherapy, gene therapy, and more. Nanoparticles possess a novel approach due to the myriad of functional groups that can create targeted treatments, though further optimization is still required. In this review, the authors will present the current uses and abilities of nanotechnology and its implication for use with immunotherapy in the treatment of GBM.
Appendix
Available only for authorised users
Literature
1.
Ohgaki H et al (2004) Genetic pathways to glioblastoma: a population-based study. Cancer Res 64:6892–6899PubMedCrossRef
2.
3.
Stupp R et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996PubMedCrossRef
4.
Vredenburgh JJ et al (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25:4722–4729PubMedCrossRef
5.
Patel MA, Kim JE, Ruzevick J, Li G, Lim M (2014) The future of glioblastoma therapy: synergism of standard of care and immunotherapy. Cancers (Basel) 6:1953–1985CrossRef
6.
7.
8.
Wohlfart S, Gelperina S, Kreuter J (2012) Transport of drugs across the blood-brain barrier by nanoparticles. J Control Release 161:264–273PubMedCrossRef
9.
10.
Wang X et al (2014) Dendritic cell-based vaccine for the treatment of malignant glioma: a systematic review. Cancer Invest 32(9):451–457PubMedCrossRef
11.
Everson RG et al (2014) Cytokine responsiveness of CD8(+) T cells is a reproducible biomarker for the clinical efficacy of dendritic cell vaccination in glioblastoma patients. J Immunother Cancer 2:10PubMedCentralPubMedCrossRef
12.
13.
Thaci B et al (2014) Significance of interleukin-13 receptor alpha 2-targeted glioblastoma therapy. Neuro Oncol 16:1304–1312PubMedCrossRef
14.
Choy W et al (2012) CD133 as a marker for regulation and potential for targeted therapies in glioblastoma multiforme. Neurosurg Clin N Am 23:391–405PubMedCrossRef
15.
Ooi YC et al (2014) The role of regulatory T-cells in glioma immunology. Clin Neurol Neurosurg 119:125–132PubMedCrossRef
16.
Choi JY et al (2009) In vitro cytotoxicity screening of water-dispersible metal oxide nanoparticles in human cell lines. Bioprocess Biosyst Eng 33:21–30PubMedCrossRef
17.
18.
19.
Ding H et al (2011) Bioconjugated PLGA-4-arm-PEG branched polymeric nanoparticles as novel tumor targeting carriers. Nanotechnology 22:165101PubMedCrossRef
20.
21.
Schottelius M, Laufer B, Kessler H, Wester HJ (2009) Ligands for mapping alphavbeta3-integrin expression in vivo. Acc Chem Res 42:969–980PubMedCrossRef
22.
Gelperina S et al (2010) Drug delivery to the brain using surfactant-coated poly(lactide-co-glycolide) nanoparticles: influence of the formulation parameters. Eur J Pharm Biopharm 74:157–163PubMedCrossRef
23.
Tahara K, Kato Y, Yamamoto H, Kreuter J, Kawashima Y (2011) Intracellular drug delivery using polysorbate 80-modified poly(d, l-lactide-co-glycolide) nanospheres to glioblastoma cells. J Microencapsul 28:29–36PubMedCrossRef
24.
Sawyer AJ et al (2011) Convection-enhanced delivery of camptothecin-loaded polymer nanoparticles for treatment of intracranial tumors. Drug Deliv Transl Res 1:34–42PubMedCentralPubMedCrossRef
25.
Petri B et al (2007) Chemotherapy of brain tumour using doxorubicin bound to surfactant-coated poly(butyl cyanoacrylate) nanoparticles: revisiting the role of surfactants. J Controll Release 117:51–58CrossRef
26.
Begley DJ (2004) Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol Ther 104:29–45PubMedCrossRef
27.
Kreuter J et al (2003) Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles. Pharm Res 20:409–416PubMedCrossRef
28.
Ambruosi A et al (2006) Biodistribution of polysorbate 80-coated doxorubicin-loaded [14C]-poly(butyl cyanoacrylate) nanoparticles after intravenous administration to glioblastoma-bearing rats. J Drug Target 14:97–105PubMedCrossRef
29.
Ambruosi A et al (2006) Influence of surfactants, polymer and doxorubicin loading on the anti-tumour effect of poly(butyl cyanoacrylate) nanoparticles in a rat glioma model. J Microencapsul 23:582–592PubMedCrossRef
30.
Steiniger SCJ et al (2004) Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. Int J Cancer 109:759–767PubMedCrossRef
31.
Jachimczak P et al (1993) The effect of transforming growth factor-beta 2-specific phosphorothioate-anti-sense oligodeoxynucleotides in reversing cellular immunosuppression in malignant glioma. J Neurosurg 78:944–951PubMedCrossRef
32.
Jachimczak P et al (1996) Transforming growth factor-beta-mediated autocrine growth regulation of gliomas as detected with phosphorothioate antisense oligonucleotides. Int J Cancer 65:332–337PubMedCrossRef
33.
Schneider T et al (2008) Brain tumor therapy by combined vaccination and antisense oligonucleotide delivery with nanoparticles. J Neuroimmunol 195:21–27PubMedCrossRef
34.
Li J et al (2011) The use of myristic acid as a ligand of polyethylenimine/DNA nanoparticles for targeted gene therapy of glioblastoma. Nanotechnology 22:435101PubMedCrossRef
35.
Sheng X et al (2012) Immunohistochemical localization of inhibin/activin subunits in the wild ground squirrel (citellus dauricus brandt) ovary. J Reprod Develop 58:531–536CrossRef
36.
Zhan C et al (2012) Co-delivery of TRAIL gene enhances the anti-glioblastoma effect of paclitaxel in vitro and in vivo. J Controll Release 160:630–636CrossRef
37.
Ofek P, Fischer W, Calderon M, Haag R, Satchi-Fainaro R (2010) In vivo delivery of small interfering RNA to tumors and their vasculature by novel dendritic nanocarriers. FASEB J 24:3122–3134PubMedCrossRef
38.
Koppu S et al (2010) Tumor regression after systemic administration of a novel tumor-targeted gene delivery system carrying a therapeutic plasmid DNA. J Controlled Release 143:215–221CrossRef
39.
Gajbhiye V, Jain NK (2011) The treatment of glioblastoma xenografts by surfactant conjugated dendritic nanoconjugates. Biomaterials 32(26):6213–6225PubMed
40.
41.
McNerny DQ et al (2009) RGD dendron bodies; synthetic avidity agents with defined and potentially interchangeable effector sites that can substitute for antibodies. Bioconjug Chem 20:1853–1859PubMedCentralPubMedCrossRef
42.
Ren Y et al (2010) Co-delivery of as-miR-21 and 5-FU by poly(amidoamine) dendrimer attenuates human glioma cell growth in vitro. J Biomater Sci Polym Ed 21:303–314PubMedCrossRef
43.
Han L et al (2010) Tat-BMPs-PAMAM conjugates enhance therapeutic effect of small interference RNA on U251 glioma cells in vitro and in vivo. Hum Gene Ther 21:417–426PubMedCrossRef
44.
Lu Y-J, Wei K-C, Ma C-CM, Yang S-Y, Chen J-P (2012) Dual targeted delivery of doxorubicin to cancer cells using folate-conjugated magnetic multi-walled carbon nanotubes. Colloids Surf B 89:1–9CrossRef
45.
46.
Hadjipanayis CG et al (2010) EGFRvIII antibody-conjugated iron oxide nanoparticles for magnetic resonance imaging-guided convection-enhanced delivery and targeted therapy of glioblastoma. Cancer Res 70:6303–6312PubMedCentralPubMedCrossRef
47.
Shultz MD et al (2011) Metallofullerene-based nanoplatform for brain tumor brachytherapy and longitudinal imaging in a murine orthotopic xenograft model. Radiology 261:136–143PubMedCentralPubMedCrossRef
48.
Bulte JW (2011) Science to practice: can theranostic fullerenes be used to treat brain tumors? Radiology 261:1–2PubMedCrossRef
49.
Shultz MD et al (2010) Encapsulation of a radiolabeled cluster inside a fullerene cage, (177)Lu(x)Lu((3-x))N@C(80): an interleukin-13-conjugated radiolabeled metallofullerene platform. J Am Chem Soc 132:4980–4981PubMedCentralPubMedCrossRef
50.
Kuo Y-C, Liang C-T (2011) Inhibition of human brain malignant glioblastoma cells using carmustine-loaded catanionic solid lipid nanoparticles with surface anti-epithelial growth factor receptor. Biomaterials 32:3340–3350PubMedCrossRef
51.
Kundu P, Mohanty C, Sahoo SK (2012) Antiglioma activity of curcumin-loaded lipid nanoparticles and its enhanced bioavailability in brain tissue for effective glioblastoma therapy. Acta Biomater 8:2670–2687PubMedCrossRef
52.
Verreault M et al (2011) Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C™), doxorubicin (Caelyx®) or vincristine. BMC Cancer 11:124PubMedCentralPubMedCrossRef
53.
Roger M et al (2012) Ferrociphenol lipid nanocapsule delivery by mesenchymal stromal cells in brain tumor therapy. Int J Pharm 423:63–68PubMedCrossRef
54.
Jin J et al (2011) In vivo specific delivery of c-Met siRNA to glioblastoma using cationic solid lipid nanoparticles. Bioconj Chem 22:2568–2572CrossRef
55.
Nikanjam M et al (2007) Synthetic nano-low density lipoprotein as targeted drug delivery vehicle for glioblastoma multiforme. Int J Pharm 328:86–94PubMedCrossRef
56.
Nikanjam M, Gibbs AR, Hunt CA, Budinger TF, Forte TM (2007) Synthetic nano-LDL with paclitaxel oleate as a targeted drug delivery vehicle for glioblastoma multiforme. J Controll Release 124:163–171CrossRef
57.
Garcion E et al (2006) A new generation of anticancer, drug-loaded, colloidal vectors reverses multidrug resistance in glioma and reduces tumor progression in rats. Mol Cancer Ther 5:1710–1722PubMedCrossRef
58.
Pinzón-Daza ML et al (2012) The association of statins plus LDL receptor-targeted liposome-encapsulated doxorubicin increases the in vitro drug delivery across blood-brain barrier cells. Br J Pharm 167(7):1431–1447CrossRef
59.
Kuo Y-C, Liang C-T (2011) Catanionic solid lipid nanoparticles carrying doxorubicin for inhibiting the growth of U87MG cells. Colloids Surf B 85:131–137CrossRef
60.
Agarwal A, Mackey MA, El-Sayed MA, Bellamkonda RV (2011) Remote triggered release of doxorubicin in tumors by synergistic application of thermosensitive liposomes and gold nanorods. ACS Nano 5:4919–4926PubMedCrossRef
61.
Wang X et al (2012) Cancer stem cell labeling using poly(l-lysine)-modified iron oxide nanoparticles. Biomaterials 33:3719–3732PubMedCrossRef
62.
Dilnawaz F et al (2012) The transport of non-surfactant based paclitaxel loaded magnetic nanoparticles across the blood brain barrier in a rat model. Biomaterials 33:2936–2951PubMedCrossRef
63.
Lee HY et al (2008) PET/MRI dual-modality tumor imaging using arginine-glycine-aspartic (RGD)-conjugated radiolabeled iron oxide nanoparticles. J Nucl Med 49:1371–1379PubMedCrossRef
64.
Zhang F et al (2012) Noninvasive monitoring of orthotopic glioblastoma therapy response using RGD-conjugated iron oxide nanoparticles. Biomaterials 33:5414–5422PubMedCentralPubMedCrossRef
65.
66.
Plotkin M et al (2006) 18F-FET PET for planning of thermotherapy using magnetic nanoparticles in recurrent glioblastoma. Int J Hyperth 22:319–325CrossRef
67.
van Landeghem FKH et al (2009) Post-mortem studies in glioblastoma patients treated with thermotherapy using magnetic nanoparticles. Biomaterials 30:52–57PubMedCrossRef
68.
Jordan A et al (2005) The effect of thermotherapy using magnetic nanoparticles on rat malignant glioma. J Neurooncol 78:7–14PubMedCrossRef
69.
Veiseh O et al (2010) Chlorotoxin bound magnetic nanovector tailored for cancer cell targeting, imaging, and siRNA delivery. Biomaterials 31:8032–8042PubMedCentralPubMedCrossRef
70.
Buehler DC et al (2014) Bioengineered vaults: self-assembling protein shell-lipophilic core nanoparticles for drug delivery. ACS Nano 8:7723–7732PubMedCrossRef
71.
Rome LH, Kickhoefer VA (2013) Development of the vault particle as a platform technology. ACS Nano 7:889–902PubMedCrossRef
72.
73.
74.
75.
Yang J et al (2012) Endogenous vaults and bioengineered vault nanoparticles for treatment of glioblastomas: implications for future targeted therapies. Neurosurg Clin N Am 23:451–458PubMedCrossRef
Metadata
Title
Nanotechnology to augment immunotherapy for the treatment of glioblastoma multiforme
Authors
Nolan Ung
Isaac Yang
Publication date
01-07-2015
Publisher
Springer US
Published in
Journal of Neuro-Oncology / Issue 3/2015
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-015-1814-1

Other articles of this Issue 3/2015

Journal of Neuro-Oncology 3/2015 Go to the issue

Editors' Invited Manuscript

Glioblastoma antigen discovery—foundations for immunotherapy

Editors' Invited Manuscript

Concepts of immunotherapy for glioma

Editors' Invited Manuscript

The role of STAT3 in tumor-mediated immune suppression

Editors' Invited Manuscript

The role of regulatory T cells and microglia in glioblastoma-associated immunosuppression

Editors' Invited Manuscript

Current challenges in designing GBM trials for immunotherapy

Editors' Invited Manuscript

Glioblastoma stem cells and stem cell-targeting immunotherapies